Multiple Effects of Resveratrol on Osteosarcoma Cell Lines

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Osteosarcoma (OS) is a prevalent bone cancer in children, presenting treatment challenges like chemoresistance and recurrence.
• Current chemotherapy regimens for OS have limitations, including adverse effects and limited efficacy.

Purpose of the Study:

• To investigate the potential of resveratrol (RSV), a natural polyphenol, as an adjuvant therapy for osteosarcoma.
• To evaluate the anti-tumor effects of RSV on OS cell lines, both alone and in combination with standard chemotherapies.

Main Methods:

• In vitro studies on osteosarcoma cell lines treated with resveratrol.
• Analysis of cell growth, differentiation markers, apoptosis pathways (AKT, caspase-3), and cytokine secretion (IL-6, IL-8).
• Investigation of epigenetic modifications on IL-6 and IL-8 promoter regions.

Main Results:

• Resveratrol demonstrated significant tumor-suppressing activities, including inhibition of cell growth and migration.
• RSV treatment led to increased osteoblastic differentiation and modulated apoptosis pathways.
• Epigenetic effects on IL-6 and IL-8 promoters were observed, reducing their secretion.
• Combination therapy of RSV with doxorubicin and cisplatin enhanced cytotoxic effects on OS cells.

Conclusions:

• Resveratrol exhibits multiple anti-cancer properties against osteosarcoma cells.
• RSV shows potential as a therapeutic adjuvant, enhancing the efficacy of conventional chemotherapy for osteosarcoma.
• Further research is warranted to explore RSV's clinical application in osteosarcoma treatment.